Evidence map›Paper›PMID 33167892›Full record

ArticleBMC infectious diseases2020

Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore.

Oluwaseun Falade-Nwulia, Jada Hackman, Shruti H Mehta, Sean D McCormick, Gregory D Kirk, Mark Sulkowski, David Thomas, Carl Latkin, Oliver Laeyendecker, Stuart C Ray

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oluwaseun Falade-NwuliaJohns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. ofalade1@jhmi.edu.ORCID http://orcid.org/0000-0003-2321-2295
Jada HackmanJohns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Shruti H MehtaJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
Sean D McCormickJohns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Gregory D KirkJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
Mark SulkowskiJohns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
David ThomasJohns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Carl LatkinJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
Oliver LaeyendeckerJohns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Stuart C RayJohns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2003 to 2018
$8.0M
HIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0M
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugsR01DA048063 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta, David L Thomas · 2019 to 2026
$4.2M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
The impact of social networks on hepatitis C transmission and care access in people who inject drugsK23DA041294 · NIDA · JOHNS HOPKINS UNIVERSITY · PI FALADE-NWULIA, OLUWASEUN · 2016 to 2020
$924k
Johns Hopkins University Doris Duke Early Clinician Investigator AwardNIAID NIH HHS P30 AI094189NIDA NIH HHS K23 DA041294NIDA NIH HHS K24 DA034621NIDA NIH HHS R01 DA016065NIDA NIH HHS R01 DA048063NIDA NIH HHS R37 DA013806NIDA NIH HHS U01 DA036935NIH HHS DA036927NIH HHS DA048063NIH HHS K23DA041294NIH HHS K24DA034621NIH HHS P30AI094189NIH HHS R01DA16065NIH HHS R37DA013806NIH HHS U01DA036935
6 · The paper itself

Abstract

backgroundThe availability of effective, oral direct acting antivirals (DAAs) for hepatitis C virus (HCV) treatment has put elimination of HCV as a public health challenge within reach. However, little is known about the characteristics of transmission networks of people who inject drugs (PWID).

methodsSequencing of a segment of the HCV genome was performed on samples collected from a community-based cohort of PWID between August 2005 and December 2016. Phylogenetic trees were inferred, and clusters were identified (70% bootstrap threshold; 0.04 maximum genetic distance threshold). We describe sex, race, age difference, and HIV infection status of potential transmission partners. Logistic regression was used to assess factors associated with being in an HCV cluster.

resultsOf 508 HCV genotype 1 viremic PWID, 8% (n = 41) were grouped into 20 clusters, consisting of 19 pairs and 1 triad. In adjusted analyses, female sex (odds ratio [OR] 2.3 [95% confidence interval (CI) 1.2-4.5]) and HIV infection (OR 5.7 [CI 2.7-11.9]) remained independently associated with being in an HCV infection cluster.

conclusionsMolecular epidemiological analysis reveals that, in this cohort of PWID in Baltimore, HIV infection and female sex were associated with HCV clustering. Combination HCV prevention interventions targeting HIV infected PWID and addressing HCV infection prevention needs of women have potential to advance HCV elimination efforts.

Indexed as

PhylogenyAgedAged, 80 and overAntiviral AgentsBaltimoreCluster AnalysisFemaleFollow-Up StudiesGenotypeHepacivirusHepatitis CHIVHIV InfectionsHumansMaleMiddle AgedAntiviral AgentsHepatitis CHIVMolecular epidemiologyPeople who inject drugsWomen

Identifiers

PMID33167892
PMCPMC7652590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.